Litcius/Paper detail

Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial

Franck Morschhauser, Hervé Tilly, Aristeidis Chaidos, Pam McKay, Tycel Phillips, Sarit Assouline, Connie Lee Batlevi, Phillip L. Campbell, Vincent Ribrag, Gandhi Damaj, Michael Dickinson, Wojciech Jurczak, Maciej Kazmierczak, Stephen Opat, John Radford, Anna Schmitt, Jay Yang, Jennifer Whalen, Shefali Agarwal, Deyaa Adib, Gilles Salles

2020The Lancet Oncology588 citationsDOIOpen Access PDF

Topics & Concepts

Open labelMedicineFollicular lymphomaRefractory (planetary science)OncologyInternal medicinePhases of clinical researchFollicular phaseClinical trialLymphomaAstrobiologyPhysicsLymphoma Diagnosis and TreatmentEpigenetics and DNA MethylationGenetic Syndromes and Imprinting
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial | Litcius